U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C19H24N2S
Molecular Weight 312.472
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PROFENAMINE

SMILES

CCN(CC)C(C)CN1C2=CC=CC=C2SC3=C1C=CC=C3

InChI

InChIKey=CDOZDBSBBXSXLB-UHFFFAOYSA-N
InChI=1S/C19H24N2S/c1-4-20(5-2)15(3)14-21-16-10-6-8-12-18(16)22-19-13-9-7-11-17(19)21/h6-13,15H,4-5,14H2,1-3H3

HIDE SMILES / InChI

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/21740955 | https://www.ncbi.nlm.nih.gov/pubmed/2904117

Ethopropazine is an anticholinergic drug. Ethopropazine is an inhibitor of butyrylcholinesterase and non-selective muscarinic acetylcholine receptor antagonist. Ethopropazine has been used for the treatment of parkinsonism and drug-induced extrapyramidal reactions. Also It used for the symptomatic treatment of hepatolenticular degeneration and congenital athetosis.

CNS Activity

Originator

Approval Year

1953
193
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
 88.0 nM [Kd]
Antagonist
2778
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
PARSIDOL

Approved Use

Ethopropazine is indicated for the treatment of parkinsonism and drug-induced extrapyramidal reactions. Also used for the symptomatic treatment of hepatolenticular degeneration and congenital athetosis.
Primary
Approved
8429
PARSIDOL

Approved Use

Ethopropazine is indicated for the treatment of parkinsonism and drug-induced extrapyramidal reactions. Also used for the symptomatic treatment of hepatolenticular degeneration and congenital athetosis.
Primary
Approved
8429
PARSIDOL

Approved Use

Ethopropazine is indicated for the treatment of parkinsonism and drug-induced extrapyramidal reactions. Also used for the symptomatic treatment of hepatolenticular degeneration and congenital athetosis.
Primary
Approved
8429
PARSIDOL

Approved Use

Ethopropazine is indicated for the treatment of parkinsonism and drug-induced extrapyramidal reactions. Also used for the symptomatic treatment of hepatolenticular degeneration and congenital athetosis.
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
7%
OTHER
https://go.drugbank.com/drugs/DB00392
PROFENAMINE unknown
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inhibitor
1612

OverviewOther

Other InhibitorOther SubstrateOther Inducer
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
1647
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:313639
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:313639
eMolecules
1986772
https://www.emolecules.com/cgi-bin/more?vid=1986772
PubMed

PubMed

TitleDatePubMed
Abnormal involuntary movements induced by anticholinergic therapy.
1974
The relative selectivity of anticholinergic drugs for the M1 and M2 muscarinic receptor subtypes.
1986
Patents

Patents

JP2009240173A
3
JP2011528908A
3
JP5329434B2
3

Sample Use Guides

In Vivo Use Guide
ETHOPROPAZINE HYDROCHLORIDE TABLETS USP Usual adult and adolescent dose Parkinsonism and Drug-induced extrapyramidal reactions Oral, 50 mg one or two times a day, the dosage being increased as needed and tolerated. In severe cases, the dose may be increased gradually to a total of 500 to 600 mg a day.
Route of Administration: Oral
In Vitro Use Guide
The racemate and the enantiomers of ethopropazine were tested in vitro for their cellular toxicity using lung fibroblast cells. Each enantiomer was shown to be cytotoxic at concentrations greater than 10 uM.
Name Type Language
PROFENAMINE
INN   WHO-DD  
INN  
Official Name English
W-483
Code English
10H-PHENOTHIAZINE-10-ETHANAMINE, N,N-DIETHYL-.ALPHA.-METHYL-
Systematic Name English
ETHOPROPAZINE [MI]
Common Name English
ETHOPROPAZINE
MI   VANDF  
Common Name English
PHENOTHIAZINE, 10-(2-(DIETHYLAMINO)PROPYL)-
Systematic Name English
(±)-PROFENAMINE
Common Name English
(±)-ETHOPROPAZINE
Common Name English
ETHOPROPAZINE [VANDF]
Common Name English
Profenamine [WHO-DD]
Common Name English
profenamine [INN]
Common Name English
10-(2-(DIETHYLAMINO)PROPYL)PHENOTHIAZINE
Systematic Name English
RP-3356
Code English
SC-2538
Code English
N,N-DIETHYL-.ALPHA.-METHYL-10H-PHENOTHIAZINE-10-ETHANAMINE
Systematic Name English
Classification Tree Code System Code
WHO-VATC QN04AA05
Created by admin on Fri Dec 15 15:28:26 UTC 2023 , Edited by admin on Fri Dec 15 15:28:26 UTC 2023
WHO-ATC N04AA05
Created by admin on Fri Dec 15 15:28:26 UTC 2023 , Edited by admin on Fri Dec 15 15:28:26 UTC 2023
NCI_THESAURUS C38149
Created by admin on Fri Dec 15 15:28:26 UTC 2023 , Edited by admin on Fri Dec 15 15:28:26 UTC 2023
Code System Code Type Description
EVMPD
SUB10071MIG
Created by admin on Fri Dec 15 15:28:26 UTC 2023 , Edited by admin on Fri Dec 15 15:28:26 UTC 2023
PRIMARY
INN
4180
Created by admin on Fri Dec 15 15:28:26 UTC 2023 , Edited by admin on Fri Dec 15 15:28:26 UTC 2023
PRIMARY
NCI_THESAURUS
C73333
Created by admin on Fri Dec 15 15:28:26 UTC 2023 , Edited by admin on Fri Dec 15 15:28:26 UTC 2023
PRIMARY
MESH
C084820
Created by admin on Fri Dec 15 15:28:26 UTC 2023 , Edited by admin on Fri Dec 15 15:28:26 UTC 2023
PRIMARY
WIKIPEDIA
PROFENAMINE
Created by admin on Fri Dec 15 15:28:26 UTC 2023 , Edited by admin on Fri Dec 15 15:28:26 UTC 2023
PRIMARY
ECHA (EC/EINECS)
208-320-4
Created by admin on Fri Dec 15 15:28:26 UTC 2023 , Edited by admin on Fri Dec 15 15:28:26 UTC 2023
PRIMARY
RXCUI
4134
Created by admin on Fri Dec 15 15:28:26 UTC 2023 , Edited by admin on Fri Dec 15 15:28:26 UTC 2023
PRIMARY RxNorm
IUPHAR
7181
Created by admin on Fri Dec 15 15:28:26 UTC 2023 , Edited by admin on Fri Dec 15 15:28:26 UTC 2023
PRIMARY
DRUG CENTRAL
1086
Created by admin on Fri Dec 15 15:28:26 UTC 2023 , Edited by admin on Fri Dec 15 15:28:26 UTC 2023
PRIMARY
CAS
115016-98-3
Created by admin on Fri Dec 15 15:28:26 UTC 2023 , Edited by admin on Fri Dec 15 15:28:26 UTC 2023
SUPERSEDED
SMS_ID
100000081139
Created by admin on Fri Dec 15 15:28:26 UTC 2023 , Edited by admin on Fri Dec 15 15:28:26 UTC 2023
PRIMARY
ChEMBL
CHEMBL1206
Created by admin on Fri Dec 15 15:28:26 UTC 2023 , Edited by admin on Fri Dec 15 15:28:26 UTC 2023
PRIMARY
MERCK INDEX
m5070
Created by admin on Fri Dec 15 15:28:26 UTC 2023 , Edited by admin on Fri Dec 15 15:28:26 UTC 2023
PRIMARY Merck Index
CAS
37342-22-6
Created by admin on Fri Dec 15 15:28:26 UTC 2023 , Edited by admin on Fri Dec 15 15:28:26 UTC 2023
SUPERSEDED
DRUG BANK
DB00392
Created by admin on Fri Dec 15 15:28:26 UTC 2023 , Edited by admin on Fri Dec 15 15:28:26 UTC 2023
PRIMARY
CAS
522-00-9
Created by admin on Fri Dec 15 15:28:26 UTC 2023 , Edited by admin on Fri Dec 15 15:28:26 UTC 2023
PRIMARY
EPA CompTox
DTXSID2023018
Created by admin on Fri Dec 15 15:28:26 UTC 2023 , Edited by admin on Fri Dec 15 15:28:26 UTC 2023
PRIMARY
FDA UNII
7WI4P02YN1
Created by admin on Fri Dec 15 15:28:26 UTC 2023 , Edited by admin on Fri Dec 15 15:28:26 UTC 2023
PRIMARY
PUBCHEM
3290
Created by admin on Fri Dec 15 15:28:26 UTC 2023 , Edited by admin on Fri Dec 15 15:28:26 UTC 2023
PRIMARY
CHEBI
313639
Created by admin on Fri Dec 15 15:28:26 UTC 2023 , Edited by admin on Fri Dec 15 15:28:26 UTC 2023
PRIMARY
ACTIVE MOIETY
Structure of PROFENAMINE
SALT/SOLVATE (PARENT)
Structure of PROFENAMINE HYDROCHLORIDE
SALT/SOLVATE (PARENT)
Structure of PROFENAMINE HIBENZATE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966